Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 plus gemcitabine vs placebo plus gemcitabine in first-line metastatic pancreatic adenocarcinoma
jRCT2080221429Phase 3
- Sponsor
- Takeda
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing AMG 479 + gemcitabine with Placebo + gemcitabine (2 arms).
02
Drugs
ganitumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080221429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221429.